BioCentury
ARTICLE | Financial News

Gilead beats Street

February 5, 2013 1:58 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q12 and 2012 earnings that beat analyst expectations. The company reported 4Q12 non-GAAP diluted EPS of $0.50, beating by $0.02 the Street's estimate of $0.48 and up a penny from $0.49 in 4Q11. Revenues for the quarter were $2.59 billion, above the Street's estimate of $2.43 billion and up 18% from $2.2 billion in 4Q11. For the year, Gilead reported non-GAAP EPS of $1.95, beating by $0.02 the Street's estimate and Gilead's year ago EPS of $1.93. Revenues for the year were $9.7 billion, up 16% from $8.4 billion in 2011. The Street was expecting $9.54 billion in revenues.

Gilead also introduced 2013 guidance and said it expects net product sales of $10-$10.2 billion, which would be a 6-9% increase over 2012. ...